Multifocal motor neuropathy – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:17:41 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Multifocal motor neuropathy – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study comparing empasiprubart versus intravenous immunoglobulin for treating adults with multifocal motor neuropathy https://clinicaltrials.eu/trial/study-of-empasiprubart-compared-to-intravenous-immunoglobulin-for-adults-with-multifocal-motor-neuropathy/ Wed, 29 Apr 2026 15:06:09 +0000 https://clinicaltrials.eu/trial/study-of-empasiprubart-compared-to-intravenous-immunoglobulin-for-adults-with-multifocal-motor-neuropathy/ This study focuses on adults with Multifocal Motor Neuropathy, a rare neurological condition that affects motor nerves and causes progressive muscle weakness. The research compares two treatments: a new medication called empasiprubart and standard therapy with intravenous immunoglobulin (a treatment made from donated blood plasma that contains antibodies). The study will also use placebo solutions for comparison purposes.

The main purpose of this research is to determine if empasiprubart is effective at improving muscle strength compared to intravenous immunoglobulin in people with Multifocal Motor Neuropathy. Both medications will be given through intravenous infusion, which means they are administered directly into a vein.

The study is divided into two parts. During the treatment period, participants will receive either empasiprubart or intravenous immunoglobulin along with their matching placebos. Throughout the study, doctors will measure changes in muscle strength and other aspects of the condition. The research team will also monitor the safety of the treatments and collect information about how well participants feel and function in their daily activities.

]]> Study on the Safety and Effects of DNTH103 for Adults with Multifocal Motor Neuropathy https://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-dnth103-for-adults-with-multifocal-motor-neuropathy/ Wed, 29 Apr 2026 15:03:34 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-dnth103-for-adults-with-multifocal-motor-neuropathy/ This clinical trial is focused on studying a condition called Multifocal Motor Neuropathy (MMN). MMN is a rare disorder that affects the nerves, leading to muscle weakness, especially in the arms and hands. The study will evaluate a new treatment called DNTH103, which is a type of medication known as a monoclonal antibody. Monoclonal antibodies are proteins designed to target specific parts of the immune system. In this study, DNTH103 will be given as a solution for injection, either through a vein (intravenous) or under the skin (subcutaneous).

The purpose of the study is to assess the safety and tolerability of DNTH103 in adults with MMN. Participants will be randomly assigned to receive either DNTH103 or a matching placebo. The study will be conducted in a double-blinded manner, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo. The study will last up to 17 weeks, during which participants will be closely monitored for any side effects and changes in their condition.

Throughout the study, various assessments will be conducted to evaluate the effects of DNTH103. These assessments will include measuring grip strength, monitoring any changes in the participants’ ability to perform daily activities, and tracking any adverse events that may occur. The study aims to provide valuable information on the potential benefits and risks of DNTH103 for individuals with MMN.

]]> Study on Long-term Safety and Effects of ARGX-117 for Adults with Multifocal Motor Neuropathy https://clinicaltrials.eu/trial/study-on-long-term-safety-and-effects-of-argx-117-for-adults-with-multifocal-motor-neuropathy/ Wed, 29 Apr 2026 14:57:15 +0000 https://clinicaltrials.eu/trial/study-on-long-term-safety-and-effects-of-argx-117-for-adults-with-multifocal-motor-neuropathy/ This clinical trial is focused on studying the long-term effects of a treatment called ARGX-117 in adults with a condition known as Multifocal Motor Neuropathy (MMN). MMN is a rare disorder that affects the nerves, leading to muscle weakness, primarily in the arms and hands. The treatment being tested, ARGX-117, is a type of medication known as a monoclonal antibody, which is a protein designed to target specific parts of the immune system. In this study, ARGX-117 is given as an infusion, which means it is administered directly into the bloodstream through a vein.

The purpose of this study is to evaluate the long-term safety and tolerability of ARGX-117 in people with MMN. Participants in the study will receive either the ARGX-117 treatment or a placebo. The study will monitor various aspects of health, including any side effects, changes in muscle strength, and overall well-being over time. Participants will have regular visits to assess their condition and the effects of the treatment.

This study is an extension of a previous trial, meaning it continues to follow participants who have already been involved in earlier research with ARGX-117. The trial aims to gather more information on how the treatment works over a longer period and to ensure it is safe for continued use. The study will help researchers understand the potential benefits and risks of using ARGX-117 for treating MMN, contributing to the development of effective therapies for this condition.

]]>